Cargando…

β-Arrestin2 is increased in liver fibrosis in humans and rodents

Detalles Bibliográficos
Autores principales:	Schierwagen, Robert, Dietrich, Peter, Klein, Sabine, Uschner, Frank Erhard, Ortiz, Cristina, Tyc, Olaf, Torres, Sandra, Hellerbrand, Claus, Sauerbruch, Tilman, Trebicka, Jonel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2020
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959505/ https://www.ncbi.nlm.nih.gov/pubmed/33144522 http://dx.doi.org/10.1073/pnas.2014337117

Ejemplares similares

Short-Term Western Diet Aggravates Non-Alcoholic Fatty Liver Disease (NAFLD) With Portal Hypertension in TGR(mREN2)27 Rats
por: Cremonese, Carla, et al.
Publicado: (2020)

Managing portal hypertension in patients with liver cirrhosis
por: Sauerbruch, Tilman, et al.
Publicado: (2018)

Beta-blockers in patients with liver cirrhosis: Pragmatism or perfection?
por: Sauerbruch, Tilman, et al.
Publicado: (2023)

Hepatic inflammasome activation as origin of Interleukin-1α and Interleukin-1β in liver cirrhosis
por: Praktiknjo, Michael, et al.
Publicado: (2021)

Neprilysin-dependent neuropeptide Y cleavage in the liver promotes fibrosis by blocking NPY-receptor 1
por: Ortiz, Cristina, et al.
Publicado: (2023)

Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver Cirrhosis
por: Klein, Sabine, et al.
Publicado: (2015)

The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis
por: Torres, Sandra, et al.
Publicado: (2021)

Future therapy of portal hypertension in liver cirrhosis – a guess
por: Sauerbruch, Tilman, et al.
Publicado: (2014)

Pre-primary and Primary Prophylaxis of Variceal Hemorrhage
por: Sauerbruch, Tilman, et al.
Publicado: (2013)

Recent Advances in Practical Methods for Liver Cell Biology: A Short Overview
por: Torres, Sandra, et al.
Publicado: (2020)

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis
por: Torres, Sandra, et al.
Publicado: (2023)

Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis
por: Schierwagen, Robert, et al.
Publicado: (2015)

TGR(mREN2)27 rats develop non-alcoholic fatty liver disease-associated portal hypertension responsive to modulations of Janus-kinase 2 and Mas receptor
por: Klein, Sabine, et al.
Publicado: (2019)

Novel Rat Model of Repetitive Portal Venous Embolization Mimicking Human Non-Cirrhotic Idiopathic Portal Hypertension
por: Klein, Sabine, et al.
Publicado: (2016)

A New Treatment for Chronic Hepatitis B and D Offers Novel Insights Into Obesity and Hepatic Steatosis
por: Schierwagen, Robert, et al.
Publicado: (2020)

Serum markers of the extracellular matrix remodeling reflect antifibrotic therapy in bile-duct ligated rats
por: Schierwagen, Robert, et al.
Publicado: (2013)

Variation in Bile Microbiome by the Etiology of Cholestatic Liver Disease
por: Tyc, Olaf, et al.
Publicado: (2020)

The non-selective Rho-kinase inhibitors Y-27632 and Y-33075 decrease contraction but increase migration in murine and human hepatic stellate cells
por: Bachtler, Nadine, et al.
Publicado: (2023)

The Role of Macrophage-Inducible C-Type Lectin in Different Stages of Chronic Liver Disease
por: Schierwagen, Robert, et al.
Publicado: (2020)

Interplay of Matrix Stiffness and c-SRC in Hepatic Fibrosis
por: Görtzen, Jan, et al.
Publicado: (2015)

Extracellular Matrix Remodeling in Chronic Liver Disease
por: Ortiz, Cristina, et al.
Publicado: (2021)

Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction
por: Sauerbruch, Tilman, et al.
Publicado: (2021)

Rho-kinase inhibitor coupled to peptide-modified albumin carrier reduces portal pressure and increases renal perfusion in cirrhotic rats
por: Klein, Sabine, et al.
Publicado: (2019)

Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension
por: Uschner, Frank E., et al.
Publicado: (2015)

The Role of miRNA-34a as a Prognostic Biomarker for Cirrhotic Patients with Portal Hypertension Receiving TIPS
por: Jansen, Christian, et al.
Publicado: (2014)

Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS
por: Queck, Alexander, et al.
Publicado: (2020)

Quantification of liver fibrosis: extracellular volume fraction using an MRI bolus-only technique in a rat animal model
por: Luetkens, Julian A., et al.
Publicado: (2019)

Baseline Presence of NAFLD Predicts Weight Loss after Gastric Bypass Surgery for Morbid Obesity
por: Rheinwalt, Karl Peter, et al.
Publicado: (2020)

The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension
por: Uschner, Frank Erhard, et al.
Publicado: (2018)

Experimental liver fibrosis research: update on animal models, legal issues and translational aspects
por: Liedtke, Christian, et al.
Publicado: (2013)

Editorial: Acute-on-chronic liver failure: systemic inflammation and immunosuppression
por: Tyc, Olaf, et al.
Publicado: (2023)

Dynamic human liver proteome atlas reveals functional insights into disease pathways
por: Niu, Lili, et al.
Publicado: (2022)

Activation of the Alternate Renin-Angiotensin System Correlates with the Clinical Status in Human Cirrhosis and Corrects Post Liver Transplantation
por: Casey, Stephen, et al.
Publicado: (2019)

Liver Fibrosis in HIV Patients Receiving a Modern cART: Which Factors Play a Role?
por: Mohr, Raphael, et al.
Publicado: (2015)

Role of circulating angiogenin levels in portal hypertension and TIPS
por: Queck, Alexander, et al.
Publicado: (2021)

Myostatin is associated with the presence and development of acute-on-chronic liver failure
por: Ruiz-Margáin, Astrid, et al.
Publicado: (2023)

Microbiome Patterns in Matched Bile, Duodenal, Pancreatic Tumor Tissue, Drainage, and Stool Samples: Association with Preoperative Stenting and Postoperative Pancreatic Fistula Development
por: Langheinrich, Melanie, et al.
Publicado: (2020)

Systemic MCP-1 Levels Derive Mainly From Injured Liver and Are Associated With Complications in Cirrhosis
por: Queck, Alexander, et al.
Publicado: (2020)

FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
por: Verbeke, Len, et al.
Publicado: (2016)

Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis
por: Queck, Alexander, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6jbuu52u8aast099ehhndtcudj